Brief: Shanghai Junshi Biosciences Says JS212 Injection Received Acceptance Notice
08/01/2025 16:56
Jan 8 (Reuters) - Shanghai Junshi Biosciences Co Ltd
688180.SS :
* JS212 INJECTION RECEIVED ACCEPTANCE NOTICE FOR
INVESTIGATIONAL
NEW DRUG APPLICATION BBY CHINA NMPA
Further company coverage: 688180.SS
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Shanghai Junshi Biosciences
See all newsBrief: Shanghai Junshi Biosciences Q3 Net Loss At 170.9 Million Yuan
Brief: Shanghai Junshi Biosciences Q3 Net Loss At 170.9 Million Yuan
Brief: Shanghai Junshi Biosciences Receives Supplemental Drug Approval From NMPA
Brief: Shanghai Junshi Biosciences's Shareholder Plans To Cut Stake
Brief: Shanghai Junshi Biosciences Gets NMPA Acceptance Notice Of Supplemental Application For Toripalimab